Mark DeWitte

1.5k total citations
21 papers, 1.1k citations indexed

About

Mark DeWitte is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Mark DeWitte has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Immunology and 7 papers in Hematology. Recurrent topics in Mark DeWitte's work include Monoclonal and Polyclonal Antibodies Research (5 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Mark DeWitte is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Mark DeWitte collaborates with scholars based in United States, Australia and United Kingdom. Mark DeWitte's co-authors include Robert Corringham, Marian T. Nakada, Geoffrey M. Anderson, Yan Li, Frances R. Balkwill, Kellie A. Charles, Susan Hoare, Uma Prabhakar, Carla de Boer and Martin Gore and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Mark DeWitte

21 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark DeWitte United States 13 532 375 323 212 108 21 1.1k
Georg Weinlich Austria 16 389 0.7× 582 1.6× 371 1.1× 180 0.8× 29 0.3× 27 1.4k
Robert E. Ettlinger United States 8 222 0.4× 394 1.1× 238 0.7× 216 1.0× 55 0.5× 8 1.5k
Paris S. Mitrou Germany 28 939 1.8× 491 1.3× 570 1.8× 169 0.8× 62 0.6× 92 2.3k
R. Kath Germany 18 454 0.9× 175 0.5× 433 1.3× 94 0.4× 39 0.4× 55 1.3k
Michael I. Jesson United States 13 666 1.3× 467 1.2× 274 0.8× 65 0.3× 62 0.6× 21 1.6k
Debra M. Meyer United States 11 393 0.7× 411 1.1× 195 0.6× 85 0.4× 70 0.6× 13 1.2k
Tohru Takashi Japan 16 184 0.3× 433 1.2× 312 1.0× 143 0.7× 193 1.8× 35 1.0k
Jean Harb France 19 248 0.5× 175 0.5× 482 1.5× 75 0.4× 48 0.4× 55 1.2k
Douglas Orr United States 11 686 1.3× 760 2.0× 318 1.0× 115 0.5× 23 0.2× 19 1.5k
Thomas C. Caffrey United States 21 507 1.0× 375 1.0× 1000 3.1× 188 0.9× 83 0.8× 36 1.5k

Countries citing papers authored by Mark DeWitte

Since Specialization
Citations

This map shows the geographic impact of Mark DeWitte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark DeWitte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark DeWitte more than expected).

Fields of papers citing papers by Mark DeWitte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark DeWitte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark DeWitte. The network helps show where Mark DeWitte may publish in the future.

Co-authorship network of co-authors of Mark DeWitte

This figure shows the co-authorship network connecting the top 25 collaborators of Mark DeWitte. A scholar is included among the top collaborators of Mark DeWitte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark DeWitte. Mark DeWitte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rojko, Jennifer L., Mark G. Evans, Bora Han, et al.. (2014). Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes. Toxicologic Pathology. 42(4). 725–764. 98 indexed citations
2.
Smith, B. Douglas, Gail J. Roboz, Roland B. Walter, et al.. (2014). First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. Blood. 124(21). 120–120. 52 indexed citations
3.
Busfield, Samantha J., Mark Biondo, Hayley S. Ramshaw, et al.. (2012). CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells. Blood. 120(21). 3598–3598. 10 indexed citations
4.
Herzog, Eva, Samantha J. Busfield, Mark Biondo, et al.. (2012). Pharmacodynamic Activity and Preclinical Safety of CSL362, a Novel Humanised, Affinity Matured Monoclonal Antibody Against Human Interleukin 3 Receptor. Blood. 120(21). 1524–1524. 8 indexed citations
5.
Robinson, Donald W., D. Eisenberg, David Cella, et al.. (2009). The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia.. PubMed. 6(6). 283–90. 43 indexed citations
6.
Wiedenmann, Bertram, Peter Malfertheiner, Helmut Friess, et al.. (2008). A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.. PubMed. 6(1). 18–25. 122 indexed citations
7.
Tookman, Adrian, et al.. (2008). Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Supportive Care in Cancer. 16(10). 1131–1140. 31 indexed citations
8.
Brown, Ewan, Kellie A. Charles, Susan Hoare, et al.. (2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer. Annals of Oncology. 19(7). 1340–1346. 140 indexed citations
9.
Roberts, Andrew W., Simon He, Kenneth F. Bradstock, et al.. (2008). A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML. Blood. 112(11). 2956–2956. 16 indexed citations
10.
Harrison, Michelle, Nick Maisey, Susan Hoare, et al.. (2007). Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. Journal of Clinical Oncology. 25(29). 4542–4549. 195 indexed citations
11.
Manges, Robert, Heather J. Sutherland, Sundar Jagannath, et al.. (2007). Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.. Blood. 110(11). 1183–1183. 3 indexed citations
12.
Li, Yan, Geoffrey M. Anderson, Mark DeWitte, & Marian T. Nakada. (2006). Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. European Journal of Cancer. 42(6). 793–802. 93 indexed citations
13.
Helft, Paul R., Richard L. Schilsky, Hedy L. Kindler, et al.. (2004). A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Clinical Cancer Research. 10(13). 4363–4368. 41 indexed citations
14.
Tolcher, Anthony W., Leonel Ochoa, Lisa A. Hammond, et al.. (2003). Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. Journal of Clinical Oncology. 21(2). 211–222. 146 indexed citations
15.
Clarke‐Pearson, Daniel L., Linda Van Le, Timothy Iveson, et al.. (2001). Oral Topotecan as Single-Agent Second-Line Chemotherapy in Patients With Advanced Ovarian Cancer. Journal of Clinical Oncology. 19(19). 3967–3975. 41 indexed citations
16.
Schiller, Joan H., Joachim von Pawel, Paul A. Clarke, et al.. (1997). 41 Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC). Lung Cancer. 18. 13–14. 11 indexed citations
17.
Kyritsis, Athanassios P., ES Newlands, Christina Brock, et al.. (1997). Phase II trial of topotecan (T) as a continuous intravenous infusion in patients (PTS) with high grade gliomas. European Journal of Cancer. 33. S203–S203. 6 indexed citations
18.
Hulstaert, Frank, Simon Van Belle, Harry Bleiberg, et al.. (1994). Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.. Journal of Clinical Oncology. 12(11). 2439–2446. 20 indexed citations
19.
Vermylen, C., et al.. (1993). Severe idiopathic congenital aplastic anemia: role of hematopoietic growth factors.. PubMed. 12(4). 413–5. 4 indexed citations
20.
DeWitte, Mark, R. J. Eberhart, & L.C. Griel. (1980). Mastitis caused by teat-dipping error.. PubMed. 75(10). 1613–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georg Weinlich Breakdown of academic impact, for papers by Robert E. Ettlinger Breakdown of academic impact, for papers by Paris S. Mitrou Breakdown of academic impact, for papers by R. Kath Breakdown of academic impact, for papers by Michael I. Jesson Breakdown of academic impact, for papers by Debra M. Meyer Breakdown of academic impact, for papers by Tohru Takashi Breakdown of academic impact, for papers by Jean Harb Breakdown of academic impact, for papers by Douglas Orr Breakdown of academic impact, for papers by Thomas C. Caffrey
Rankless by CCL
2026